English
Back
Open Account
牛牛名人追蹤
wrote a column · Apr 17 15:03

Tracking Cathie Wood: Profit-taking at highs! CareDx surges 27%, Wood decisively sells 210,000 shares

After an unusual 'two consecutive days of zero trading activity,' Cathie Wood finally broke her silence. Her first move after returning from vacation was an extremely precise cut targeting the precision medical diagnostics company that had just seen a big surge overnight. $CareDx (CDNA.US)$ 。
After an unusual 'two consecutive days of zero trading activity,' Cathie Wood finally broke her silence. Her first move after returning from vacation was an extremely precise cut targeting the precision medical diagnostics company that had just seen a big surge overnight. $CareDx (CDNA.US)$ 。 This was not a random reduction in holdings but a classic tactical 'selling on the rise' sniper move. She sold as many as 210,600 shares of CareDx, the precision medicine and organ transplant diagnostics company, in a single day. The background to this trade is highly eye-catching. In the overnight session, CDNA experienced a strong surge. While ordinary investors might lament not getting in earlier, Cathie Wood decisively moved in the opposite direction, dumping as many as 210,000 shares directly onto the chasing-high buyers. Considering ARK's recent overall strategy in the healthcare sector (aggressively buying TEM's healthcare big data repository, WGS genomic data, and ARCT gene rewriting therapy), we can clearly see a main thread: moving from 'single niche diagnostics' to a comprehensive upgrade towards 'underlying big data models.' CareDx is indeed a leader in the field of organ transplant rejection diagnostics, but its business model is relatively vertical and may lack the 'infinite data flywheel' potential like TEM has, which feeds into a universal healthcare big model. Taking advantage of the overnight surge, converting these 'veterans in vertical fields' into profits while locking in gains, also reserves sufficient cash for subsequent investments in true AI healthcare infrastructure...
This was not a random reduction in holdings but a classic tactical 'selling on the rise' sniper move. She sold as many as 210,600 shares of CareDx, the precision medicine and organ transplant diagnostics company, in a single day.
After an unusual 'two consecutive days of zero trading activity,' Cathie Wood finally broke her silence. Her first move after returning from vacation was an extremely precise cut targeting the precision medical diagnostics company that had just seen a big surge overnight. $CareDx (CDNA.US)$ 。 This was not a random reduction in holdings but a classic tactical 'selling on the rise' sniper move. She sold as many as 210,600 shares of CareDx, the precision medicine and organ transplant diagnostics company, in a single day. The background to this trade is highly eye-catching. In the overnight session, CDNA experienced a strong surge. While ordinary investors might lament not getting in earlier, Cathie Wood decisively moved in the opposite direction, dumping as many as 210,000 shares directly onto the chasing-high buyers. Considering ARK's recent overall strategy in the healthcare sector (aggressively buying TEM's healthcare big data repository, WGS genomic data, and ARCT gene rewriting therapy), we can clearly see a main thread: moving from 'single niche diagnostics' to a comprehensive upgrade towards 'underlying big data models.' CareDx is indeed a leader in the field of organ transplant rejection diagnostics, but its business model is relatively vertical and may lack the 'infinite data flywheel' potential like TEM has, which feeds into a universal healthcare big model. Taking advantage of the overnight surge, converting these 'veterans in vertical fields' into profits while locking in gains, also reserves sufficient cash for subsequent investments in true AI healthcare infrastructure...
The background to this trade is highly eye-catching. In the overnight session, CDNA experienced a strong surge. While ordinary investors might lament not getting in earlier, Cathie Wood decisively moved in the opposite direction, dumping as many as 210,000 shares directly onto the chasing-high buyers.
Considering ARK's recent overall strategy in the healthcare sector (aggressively buying TEM's healthcare big data repository, WGS genomic data, and ARCT gene rewriting therapy), we can clearly see a main thread: moving from 'single niche diagnostics' to a comprehensive upgrade towards 'underlying big data models.' CareDx is indeed a leader in the field of organ transplant rejection diagnostics, but its business model is relatively vertical and may lack the 'infinite data flywheel' potential like TEM has, which feeds into a universal healthcare big model. Taking advantage of the overnight surge, converting these 'veterans in vertical fields' into profits while locking in gains, also reserves sufficient cash ammunition for subsequent investments in true AI healthcare infrastructure.
Futubull's [Opportunities Page] has launched a feature to track celebrity portfolio opportunities! Choose from multiple celebrity portfolios, one-click follow the moves of top investors, precisely lock in high-quality stocks, and invest with greater confidence!
After an unusual 'two consecutive days of zero trading activity,' Cathie Wood finally broke her silence. Her first move after returning from vacation was an extremely precise cut targeting the precision medical diagnostics company that had just seen a big surge overnight. $CareDx (CDNA.US)$ 。 This was not a random reduction in holdings but a classic tactical 'selling on the rise' sniper move. She sold as many as 210,600 shares of CareDx, the precision medicine and organ transplant diagnostics company, in a single day. The background to this trade is highly eye-catching. In the overnight session, CDNA experienced a strong surge. While ordinary investors might lament not getting in earlier, Cathie Wood decisively moved in the opposite direction, dumping as many as 210,000 shares directly onto the chasing-high buyers. Considering ARK's recent overall strategy in the healthcare sector (aggressively buying TEM's healthcare big data repository, WGS genomic data, and ARCT gene rewriting therapy), we can clearly see a main thread: moving from 'single niche diagnostics' to a comprehensive upgrade towards 'underlying big data models.' CareDx is indeed a leader in the field of organ transplant rejection diagnostics, but its business model is relatively vertical and may lack the 'infinite data flywheel' potential like TEM has, which feeds into a universal healthcare big model. Taking advantage of the overnight surge, converting these 'veterans in vertical fields' into profits while locking in gains, also reserves sufficient cash for subsequent investments in true AI healthcare infrastructure...
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Lol
1
Thumbs Up
3
22K Views
Report
Comment (1)
Write a Comment...
1
4
3